Literature DB >> 8662742

Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2.

R Condie1, A Herring, W S Koh, M Lee, N E Kaminski.   

Abstract

Cannabinoid receptors negatively regulate adenylate cyclase through a pertussis toxin-sensitive GTP-binding protein. In the present studies, signaling via the adenylate cyclase/cAMP pathway was investigated in the murine thymoma-derived T-cell line, EL4.IL-2. Northern analysis of EL4.IL-2 cells identified the presence of 4-kilobase CB2 but not CB1 receptor-subtype mRNA transcripts. Southern analysis of genomic DNA digests for the CB2 receptor demonstrated identical banding patterns for EL4.IL-2 cells and mouse-derived DNA, both of which were dissimilar to DNA isolated from rat. Treatment of EL4.IL-2 cells with either cannabinol or Delta9-THC disrupted the adenylate cyclase signaling cascade by inhibiting forskolin-stimulated cAMP accumulation which consequently led to a decrease in protein kinase A activity and the binding of transcription factors to a CRE consensus sequence. Likewise, an inhibition of phorbol 12-myristate 13-acetate (PMA)/ionomycin-induced interleukin 2 (IL-2) protein secretion, which correlated to decreased IL-2 gene transcription, was induced by both cannabinol and Delta9-THC. Further, cannabinoid treatment also decreased PMA/ionomycin-induced nuclear factor binding to the AP-1 proximal site of the IL-2 promoter. Conversely, forskolin enhanced PMA/ionomycin-induced AP-1 binding. These findings suggest that inhibition of signal transduction via the adenylate cyclase/cAMP pathway induces T-cell dysfunction which leads to a diminution in IL-2 gene transcription.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8662742     DOI: 10.1074/jbc.271.22.13175

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Impaired NFAT and NFκB activation are involved in suppression of CD40 ligand expression by Δ(9)-tetrahydrocannabinol in human CD4(+) T cells.

Authors:  Thitirat Ngaotepprutaram; Barbara L F Kaplan; Norbert E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  2013-08-30       Impact factor: 4.219

Review 2.  Effects of Cannabinoids on T-cell Function and Resistance to Infection.

Authors:  Toby K Eisenstein; Joseph J Meissler
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-16       Impact factor: 4.147

3.  Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940.

Authors:  John W Huffman; Alicia L S Thompson; Jenny L Wiley; Billy R Martin
Journal:  Bioorg Med Chem       Date:  2007-09-22       Impact factor: 3.641

Review 4.  The complications of promiscuity: endocannabinoid action and metabolism.

Authors:  S P H Alexander; D A Kendall
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

Review 5.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

Review 6.  The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products.

Authors:  Lisa K Brents; Paul L Prather
Journal:  Drug Metab Rev       Date:  2013-09-24       Impact factor: 4.518

7.  Synthesis and pharmacology of 1-methoxy analogs of CP-47,497.

Authors:  John W Huffman; Seon A Hepburn; Patricia H Reggio; Dow P Hurst; Jenny L Wiley; Billy R Martin
Journal:  Bioorg Med Chem       Date:  2010-06-22       Impact factor: 3.641

Review 8.  Cannabinoid receptors and their endogenous agonist, anandamide.

Authors:  J Axelrod; C C Felder
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

Review 9.  Medical cannabis for chronic pain: can it make a difference in pain management?

Authors:  Mari Kannan Maharajan; Yu Jing Yong; Hong Yang Yip; Sze Shee Woon; Kar Mon Yeap; Khai Yeng Yap; Shuen Chi Yip; Kai Xian Yap
Journal:  J Anesth       Date:  2019-09-18       Impact factor: 2.078

10.  Suppression of T cell costimulator ICOS by Delta9-tetrahydrocannabinol.

Authors:  Haitian Lu; Barbara L F Kaplan; Thitirat Ngaotepprutaram; Norbert E Kaminski
Journal:  J Leukoc Biol       Date:  2008-11-06       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.